IL6 and COVID-19: Our in vitro study has shown that CVL218 can effectively inhibit the production of several inflammatory cytokines induced by LPS in PBMCs, including IL-6, IL-10, IFN-γ, and TNF-α, which are highly related to the pathogenic characteristics of COVID-19 (Fig. 4).